Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5

Immunological Investigations

Volumn 43, Issue 3, 2014, Pages 224-235

  Xu, Lili ^a   Bao, Linlin ^a   Li, Fengdi ^a   Lv, Qi ^a   Yuan, Jing ^a   Xu, Yanfeng ^a   Deng, Wei ^a   Yao, Yanfeng ^a   Yu, Pin ^a   Qin, Chuan ^a  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Adjuvant; C48 80; Influenza; Vaccine

Indexed keywords

ADJUVANT; ANTIGEN; C48 80 ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MAST CELL; MDCK CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; VIRUS INACTIVATION; VIRUS STRAIN; VIRUS TYPING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; FEMALE; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MAST CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLYMERS; VACCINES, INACTIVATED;

EID: 84896298795     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.859155     Document Type: Article

References (23)

1. Abraham SN, St John AL. (2010). Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol, 10, 440-52.
2. Atmar RL, Keitel WA. (2009). Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol, 333, 323-44.
3. Davies WL, Grunert RR, Haff RF, et al. (1964). Antiviral activity of 1-Adamantanamine (Amantadine). Science, 144, 862-3.
4. Eisenbarth SC, Colegio OR, O?Connor W, et al. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 453, 1122-6.
5. Friedewald WF. (1944). Adjuvants in immunization with influenza virus vaccines. J Exp Med, 80, 477-91.
6. Galli SJ, Nakae S, Tsai M. (2005). Mast cells in the development of adaptive immune responses. Nat Immunol, 6, 135-42.
7. Marshall JS, King CA, McCurdy JD. (2003). Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr Pharm Des, 9, 11-24.
8. McGowen AL, Hale LP, Shelburne CP, et al. (2009). The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine, 27, 3544-52.
9. McLachlan JB, Shelburne CP, Hart JP, et al. (2008). Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med, 14, 536-41.
10. Meng S, Liu Z, Xu L, et al. (2011). Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice. PLoS One, 6, e19863.
11. Mutsch M, Zhou W, Rhodes P, et al. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell?s palsy in Switzerland. N Engl J Med, 350, 896-903.
12. Nakae S, Suto H, Kakurai M, et al. (2005). Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA, 102, 6467-72.
13. Nakae S, Suto H, Iikura M, et al. (2006). Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol, 176, 2238-48.
14. Paton WD. (1951). Compound 48/80: a potent histamine liberator. Br J Pharmacol Chemother, 6, 499-508.
15. Pizza M, Giuliani MM, Fontana MR, et al. (2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 19, 2534-41.
16. Pulendran B, Ono SJ. (2008). A shot in the arm for mast cells. Nat Med, 14, 489-90.
17. Rappuoli R, Pizza M, Douce G, Dougan G. (1999). Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today, 20, 493-500.
18. Reed LJ, Muench H. (1938). A simple method of estimating fifty percent endpoints. Amer J Hyg, 27, 493-7.
19. Ren SR, Xu LB,Wu ZY, et al. (2010). Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation. Cell Immunol, 263, 204-11.
20. Rothschild AM. (1970). Mechanisms of histamine release by compound 48-80. Br J Pharmacol, 38, 253-62.
21. Webby RJ, Webster RG. (2003). Are we ready for pandemic influenza? Science, 302, 1519-22.
22. Williams NA, Hirst TR, Nashar TO. (1999). Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunol Today, 20, 95-101.
23. Xu L, Bao L, Li F, et al. (2011). Adaption of seasonal H1N1 influenza virus in mice. PLoS One, 6, e28901.